— First clinical data presented from WU-CART-007 program; data highlight promising safety profile and preliminary anti-tumor activity in patients with R/R T-ALL/LBL —
— Additional clinical data showcase the ability of WU-NK-101 to engage the adaptive immune system and suggest the potential for durable effectiveness in patients with R/R AML —
ST.LOUIS, MO and SAN DIEGO, CA, May 11, 2023 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced an oral presentation and an onsite poster presentation highlighting data from Wugen’s WU-NK-101 and WU-CART-007 programs at the European Hematology Association (EHA) 2023 Congress, taking place from June 8 – 11, 2023 in Frankfurt, Germany.
The oral presentation includes clinical data demonstrating the unique ability of memory-like natural killer cells to engage the adaptive immune system, and the potential for durable effectiveness in the relapsed or refractory (R/R) acute myeloid leukemia (AML) setting. The poster presentation includes new clinical data highlighting the promising safety profile of WU-CART-007 and preliminary evidence of anti-leukemic activity in patients with R/R T-cell acute lymphoblastic leukemia (T-ALL)/lymphoblastic lymphoma (LBL). This will be the first clinical data presented from Wugen’s WU-CART-007 program.
The details of Wugen’s presentations at EHA are as follows:
Title: Adoptively Infused Memory-Like (ML) Natural Killer (NK) Cells Elicit Adaptive Immune Responses in Patients with Acute Myeloid Leukemia (AML)
Session: S433 – AML Biology, Microenvironment and Drug Resistance
Session Date and Time: Saturday, June 10, 2023 from 4:30 – 5:45 p.m. CEST
Location: Hall 3.2
Presenter: Sergio Rutella, M.D., Ph.D., FRCPath, FRSB, Professor of Cancer Immunotherapy at Nottingham Trent University
Abstract Code: S129
———-
Title: Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cell in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL)
Session Date and Time: Friday, June 9, 2023 from 6:00 – 7:00 p.m. CEST
Presenter: Kenneth Jacobs, M.D., Vice President of Pharmacovigilance and Clinical Development, Wugen
Abstract Code: P356
Additional meeting information can be found at https://ehaweb.org/congress/eha2023-hybrid-congress/eha2023/.
About WU-CART-007
WU-CART-007 is an allogeneic, off-the-shelf, fratricide-resistant CD7-targeted CAR-T cell therapy engineered to overcome the technological challenges of harnessing CAR-T cells to treat CD7+ hematological malignancies. Wugen is deploying CRISPR/Cas9 gene editing technology to delete CD7 and the T-cell receptor alpha constant (TRAC), preventing CAR-T cell fratricide and mitigating the risk of graft-versus-host-disease (GvHD). WU-CART-007 is manufactured using healthy donor-derived T-cells to eliminate the risk of malignant cell contamination historically observed in the autologous CAR-T setting. WU-CART-007 is currently being evaluated in a global Phase 1/2 clinical trial for the treatment of relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL)/lymphoblastic lymphoma (LBL). Additional information is available on clinicaltrials.gov, identifier NCT# 04984356.
About WU-NK-101
WU-NK-101 is a novel immunotherapy harnessing the power of memory natural killer (NK) cells to treat liquid and solid tumors. Memory NK cells are hyper-functional, long-lasting immune cells that exhibit enhanced anti-tumor activity and a cytokine-induced memory-like (CIML) phenotype. This rare cell population has a superior phenotype, proliferation capacity, and metabolic fitness that makes it better suited for cancer therapy than other NK cell therapies. Wugen is applying its proprietary MonetaTM platform to advance WU-NK-101 as a commercially scalable, off-the-shelf cell therapy for cancer. WU-NK-101 is currently in development for acute myelogenous leukemia (AML) and solid tumors.
About Wugen
Wugen, Inc., is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer. Wugen is leveraging its proprietary MonetaTM platform and deep genomic engineering expertise to pioneer a new class of memory NK cell therapies to treat hematological and solid tumor malignancies. For more information, please visit www.wugen.com.
Investor Contact:
Elsie Yau, Stern Investor Relations, Inc.
212-698-8700
elsie.yau@sternir.com
